Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings PLC, a biotech firm specializing in kinase inhibitors for cancer and autoimmune diseases, has issued 3 million new shares to RiverFort Global Opportunities. The company, which has a remaining balance of approximately £0.22 million under the financing facility, plans to settle this balance with Subscription Shares before the due date in August 2025. There will be no further withdrawals from the facility, and the total number of Ordinary Shares after Admission will be 104,578,309, which also represents the total voting rights.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
